Over the last decade, liquid biopsy has gained much attention as a powerful tool in
personalized medicine, since it enables monitoring cancer evolution and follow-up of cancer …

As per the WHO, colorectal cancer (CRC) caused around 935,173 deaths worldwide in 2020
in both sexes and at all ages. The available anticancer therapies including chemotherapy …

Molecular stratification can improve the management of advanced cancers, but requires
relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a …

Background Optimal patient selection for neoadjuvant chemotherapy prior to surgical
extirpation is limited by the inaccuracy of contemporary clinical staging methods in high-risk …

Precision medicine has transformed the way urothelial carcinoma is managed. However,
current practices are limited by the availability of tissue samples for genomic profiling and …

Context Bladder and kidney cancers require invasive procedures for definitive diagnosis,
and bladder cancer requires repeated procedures to monitor for disease recurrence. Given …

Bladder cancer (BC) is a heterogeneous disease that characterized by genomic instability
and a high mutation rate. Heterogeneity in tumor may partially explain the diversity of …

The types of urothelial carcinoma (UC) include urothelial bladder cancer and upper tract
urothelial carcinoma. Current diagnostic techniques cannot meet the needs of patients …

Purpose: Circulating tumor cells (CTC) are under investigation as a minimally invasive liquid
biopsy that may improve risk stratification and treatment selection. CTCs uniquely allow for …

Background Pembrolizumab is a new standard of care for patients with platinum-treated,
metastatic urothelial carcinoma (UC). Nab-paclitaxel is active in advanced UC. In the …